Human ABI3 (Q9P2A4), also known as NESH, is an ABI-family adaptor protein with
an N-terminal WAVE-binding region, proline-rich regions, and a C-terminal SH3
domain. Its most defensible core function is as an Abi-subunit option in the
WAVE regulatory complex (WRC/SCAR complex), where it modulates actin-dependent
cell projection, lamellipodium, and migration phenotypes.
Key evidence anchors:
- UniProt describes ABI3 as an ABI-family protein and records cytoplasmic
localization: "Belongs to the ABI family" and "Cytoplasm"
[file:human/ABI3/ABI3-uniprot.txt].
- The Falcon synthesis identifies ABI3 as an "ABI-family adaptor protein" and
an "Abi subunit option" within the WRC [file:human/ABI3/ABI3-deep-research-falcon.md].
- The primary NESH/WAVE study supports WRC membership: "Immunoprecipitation
revealed that NESH (Abi-3) is present in the Abi/WAVE complex" PMID:17101133.
- The WAVE2-complex study supports ABI3-specific protrusion effects: "the
formation of peripheral lamellipodial structures was disturbed" PMID:26428302.
- The Falcon synthesis reports that ABI3 is microglia-enriched and that Abi3
loss reduces microglial dynamic surveillance area to about 52-53% in knockout
mice versus about 73-75% in wild type [file:human/ABI3/ABI3-deep-research-falcon.md].
ABI3 should be curated primarily as a signaling adaptor/WRC component that tunes
Arp2/3-dependent actin organization. The review treats SCAR/WAVE complex
membership, actin cytoskeleton organization, regulation of cell migration, and
negative regulation of lamellipodium assembly as the main functional axis.
ABI3 is not an enzyme or transporter. Broad migration, tumor-suppression, immune,
or Alzheimer disease model phenotypes are best interpreted through the WRC and
microglial actin/surveillance mechanism unless direct biochemical evidence
supports a more specific molecular function.
The actin-filament-binding annotations remain an evidence gap. They are plausible
from ABI-family/WRC biology, but a direct intrinsic ABI3 actin-binding activity
should not be assumed without purified-protein assays.
ABI3 is a replicated late-onset Alzheimer disease risk gene, especially through
the S209F variant. For this GO review, the biologically grounded disease-relevant
axis is microglial actin regulation: WRC composition, process extension,
ramification, migration, phagolysosomal state, and plaque engagement. Hypotheses
about downstream disease progression should stay outside core GO function
curation unless they can be reduced to evolved ABI3 molecular or cellular
functions.
Mouse model evidence is useful but must be interpreted carefully. Several studies
use Abi3/Gngt2 locus perturbations, and the Falcon report notes model-dependent
effects on amyloid versus tau phenotypes. This supports mechanistic caution:
curate the actin-adaptor and microglial surveillance biology, not a generic
"Alzheimer progression" function.
The ABI3 review already validated cleanly and had second-pass cleanup recorded
in the project log before this notes file was added. The remaining gap was the
absence of a local notes journal. No YAML action changes were made in this pass.
Open expert questions already captured in the YAML:
- Does ABI3 directly bind actin filaments, or does it only regulate actin through
WRC/adaptor functions?
- How does ABI3 expression differ between microglia, neurons, and other CNS cell
types under physiological conditions?
- How does the S209F Alzheimer risk variant alter WRC incorporation,
phosphorylation, migration, phagocytosis, and microglial surveillance?
- How do phosphorylation sites S213, S216, and S342 regulate ABI3 stability and
WRC incorporation in vivo?
GO:0030334 (regulation of cell migration, IBA and IDA PMID:11956071): Retained as ACCEPT at the sign-neutral term rather than refining to GO:0030336 (negative regulation of cell migration), because all directional motility-suppression evidence (PMID:11956071 reduced motility in NESH transfectants; PMID:26428302 reduced WAVE2 plasma-membrane translocation upon exogenous NESH/Abi-3 expression) comes from forced/ectopic overexpression, whereas endogenous loss-of-function migration directionality in microglia remains unestablished.GO:0002357 (defense response to tumor cell, IEA and IMP PMID:21223585): Harmonized to MARK_AS_OVER_ANNOTATED (cell-autonomous motility/senescence modulation upon ectopic ABI3 re-expression in carcinoma cell lines rather than host immune defense against tumor cells).GO:0005515 IPI rows (MODIFY -> GO:0035591 on PMID:17101133; REMOVE on eight high-throughput binary interactome rows), harmonized GO:0042802 (identical protein binding) to KEEP_AS_NON_CORE, hedged the C-terminal SH3 PAK interaction per PMID:11956071 ("seems to interact"), recorded correctness: UNVERIFIED (full_text_unavailable: true) on the title-only Ann Oncol letter PMID:18480067, grounded GO:0048858 IBA and GO:0005515 IPI (PMID:17101133) on "Abi/WAVE complex" incorporation matching PMID:17101133's exact abstract wording (without adding "heteropentameric" where only abstract-only PMID:17101133 is cited, and without PMID:26428302's lamellipodia-disturbance quote) and noted how GO:0030036 (actin cytoskeleton organization) sits on a distinct GO branch from GO:0010593/GO:0030334, and explicitly documented curator deference on abstract-only/title-only curations (PMID:17101133 GO:0030027 IBA/IDA backed solely by PMID:17101133 WRC co-IP without PMID:26428302, PMID:11956071 GO:0030334 IDA and GO:0005737 NAS—with optional supported_by omitted on the GO:0005737 NAS row because PMID:11956071's abstract lacks a subcellular localization quotation and cytoplasmic localization is supported by GO_REF:0000054—and PMID:18480067 GO:1900028 NAS).